Latest news with #GateBioscience
Yahoo
3 days ago
- Business
- Yahoo
Eli Lilly (LLY) Gains CHMP Approval for Donanemab in Alzheimer's Treatment
Eli Lilly recently received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for its Alzheimer's drug donanemab, underscoring the company's advancements in a crucial therapeutic area. During the same period, LLY registered a 5% share price increase, notably outpacing the broader market's 1% rise over the past week. This uptrend in LLY's stock could be attributed to investors' optimism about donanemab's potential impact. Additionally, the company's collaboration with Gate Bioscience to develop novel therapies further strengthens its innovative capabilities, adding weight to its share price momentum amid broader market gains. We've spotted 2 risks for Eli Lilly you should be aware of, and 1 of them doesn't sit too well with us. Find companies with promising cash flow potential yet trading below their fair value. The recent positive opinion from the CHMP about Eli Lilly's Alzheimer's drug, donanemab, could significantly enhance the company's revenue and earnings forecasts. This development positions the company well for future growth, adding credibility to its strategic focus on expanding into high-demand therapeutic areas like oncology and immunology. Coupled with its collaboration with Gate Bioscience, these advances may provide substantial long-term benefits to the company's bottom line. Over the past five years, Eli Lilly's total return, which includes both share price growth and dividends, was a very large 473.44%. This long-term growth far outpaces the recent 1% rise in the broader market over the past year, bolstering investor confidence in the company's strategic trajectory and robust pipeline. In comparison to the US Pharmaceuticals industry, which saw a decline of 5.9% over the past year, Eli Lilly's sharp uptick in share price highlights its strong performance relative to industry peers. The company's earnings growth was a robust 80.9% over the past year, indicative of its potent execution in a challenging market. The current share price of US$812.69, when set against the analyst consensus price target of US$952.27, suggests there is room for potential growth. However, it also indicates investor caution, likely weighed down by concerns over competitive pressure and pricing dynamics. Investors might find reassurance in the company's ongoing manufacturing and R&D investments, which aim to mitigate risks and sustain growth in the coming years. Understand Eli Lilly's track record by examining our performance history report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include LLY. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
National Post
5 days ago
- Business
- National Post
Gate Bioscience Enters into a Collaboration and License Agreement with Lilly to Discover and Develop Molecular Gate Medicines
Article content BRISBANE, Calif. — Gate Bioscience, a biotechnology company developing molecular gates, a new class of small molecule drugs to eliminate disease-causing proteins at their source, today announced a collaboration and license agreement with Eli Lilly and Company ('Lilly') to discover, develop, and commercialize molecular gate therapeutics. The collaboration will leverage Gate's molecular gate drug discovery engine to identify molecular gates capable of eliminating specific difficult-to-drug proteins, bringing forth medicines with a new mechanism of action for diseases of high unmet medical need. Article content 'This collaboration fuels our vision to make molecular gates into medicines,' said Jordi Mata-Fink, Ph.D., co-founder and CEO of Gate. 'Our drugs eliminate disease-causing proteins at their source with a convenient pill. Lilly's expertise in developing innovative therapeutics to address unmet medical needs for the benefit of patients stands apart. Lilly is an ideal partner for Gate as we develop the first wave of molecular gate drugs.' Article content Under the terms of the agreement, Gate will receive an upfront payment and equity investment, will be eligible to receive milestone payments upon achievement of certain development, regulatory, and commercial milestones, as well as tiered royalties on global net sales. Gate can also receive certain preclinical R&D support from Lilly ExploR&D, a pillar of Lilly Catalyze360, for their internal programs. Article content 'Lilly has shown its commitment to building the biotech ecosystem through win-win partnerships with innovative start-up companies,' said Vineeta Agarwala, M.D., Ph.D., board member at Gate and general partner at a16z Bio + Health. 'With this collaboration, Lilly gains access to a transformative new drug modality and Gate taps into Lilly's deep expertise in delivering meaningful therapeutics. Ultimately, patients will be the big winners.' Article content About Gate Bioscience Article content Gate Bioscience is creating a new class of medicines called molecular gates, small molecules that eliminate a disease-causing secreted or membrane protein at its source. Secreted and membrane proteins pass through a common channel in the cell before they are secreted into the body. Molecular Gates recognize and block a specific protein from crossing the channel, causing it to be degraded by the cell instead of being secreted. By eliminating the harmful protein at its source, Gate aims to eliminate the disease for patients. Founded in 2021, Gate is backed by Versant Ventures, a16z Bio + Health, ARCH Venture Partners, and GV. Learn more at Article content Article content Article content Article content
